Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Theracurmin for ALS
NCT04499963Phase 2Completed
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Theracurmin in amyotrophic lateral sclerosis (ALS). Started Aug 2020; status: completed.
02
Drugs
Theracurmin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04499963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499963.